Evidence map›Paper›PMID 29276100›Full record

ReviewKidney international2018

Revisiting RAAS blockade in CKD with newer potassium-binding drugs.

Panagiotis I Georgianos, Rajiv Agarwal

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Kidney international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 3 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Review
  10. Article
  11. Management of hyperkalemia: Expert consensus from Kuwait - a Modified Delphi Approach.International journal of nephrology and renovascular disease · 2024
    Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Panagiotis I GeorgianosDivision of Nephrology and Hypertension, 1st Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Rajiv AgarwalDepartment of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, Indiana, USA. Electronic address: ragarwal@iupui.edu.
Aristotle University of Thessaloniki · GRIndiana University School of Medicine

Funding

ChLorthalidone In Chronic Kidney Disease (CLICK) StudyR01HL126903 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI AGARWAL, RAJIV · 2016 to 2020
$3.2M
Masked Hypertension in Chronic Kidney DiseaseI01CX000829 · VA · RLR VA MEDICAL CENTER · PI AGARWAL, RAJIV · 2013 to 2016
–
CSRD VA I01 CX000829NHLBI NIH HHS R01 HL126903
6 · The paper itself

Abstract

Among patients with proteinuric chronic kidney disease (CKD), current guideline recommendations mandate the use of agents blocking the renin angiotensin aldosterone system (RAAS) as first-line antihypertensive therapy based on randomized trials demonstrating that RAAS inhibitors are superior to other antihypertensive drug classes in slowing nephropathy progression to end-stage renal disease. However, the opportunities for adequate RAAS blockade in CKD are often limited, and an important impediment is the risk of hyperkalemia, especially when RAAS inhibitors are used in maximal doses or are combined. Accordingly, a large proportion of patients with proteinuric CKD may not have the anticipated renoprotective benefits since RAAS blockers are often discontinued due to incident hyperkalemia or are administered at suboptimal doses for fear of the development of hyperkalemia. Two newer potassium binders, patiromer and sodium zirconium cyclosilicate (ZS-9), have been shown to effectively and safely reduce serum potassium levels and maintain long-term normokalemia in CKD patients receiving background therapy with RAAS inhibitors. Whether these novel potassium-lowering therapies can overcome the barrier of hyperkalemia and enhance the tolerability of RAAS inhibitor use in proteinuric CKD awaits randomized trials.

Indexed as

Angiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersAnimalsBiomarkersChelating AgentsHumansHyperkalemiaPotassiumRenal Insufficiency, ChronicRenin-Angiotensin SystemRisk FactorsTreatment OutcomeAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersBiomarkersChelating AgentsPotassiumchronic kidney diseasehyperkalemiapatiromerRAAS blockadesodium zirconium cyclosilicate

Identifiers

PMID29276100
PMCPMC5794635
OpenAlexW2777100344

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.